NCT01721785View on ClinicalTrials.gov

Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer

CompletedOBSERVATIONAL
Enrollment

307

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Rectal NeoplasmsMagnetic Resonance ImagingNeoplasms Staging
Interventions
DRUG

GADOFOSVESET TRISODIUM 244 Mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Ablavar]

Gadofosveset will be used as a lymph-node specific MRI contrast agent and will be administered by manual injection as a single intravenous bolus during MRI.

Trial Locations (10)

6401 CX

Atrium Medisch Centrum, Heerlen

6202 AZ

Maastricht University Medical Center, Maastricht

6130 MB

Orbis Medisch Centrum, Sittard-Geleen

5912 BL

Viecuri Medisch Centrum, Venlo

5223 GZ

Jeroen Bosch Ziekenhuis, 's-Hertogenbosch

4800 RL

Amphia Ziekenhuis, Breda

5623 EJ

Catharina Ziekenhuis, Eindhoven

5500 MB

Maxima Medisch Centrum, Veldhoven

1100 DD

AMC, Amsterdam

7600 SZ

ZGT, Almelo

All Listed Sponsors
collaborator

Dutch Cancer Society

OTHER

lead

Maastricht University Medical Center

OTHER

NCT01721785 - Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer | Biotech Hunter | Biotech Hunter